BioSpace News Archive

The broken 340B program, designed to provide affordable care for at-risk patients, creates massive profits for providers without necessarily improving patient health outcomes and should be reformed, finds a new issue brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute.

Vivalink, a leading provider of digital healthcare solutions, announces physiological data from a wide range of the world’s leading wearable technology are available with the company’s Biometrics Data Platform for clinical trials and healthcare.

Trialbee, the leader in data and technology-based patient recruitment and enrollment for clinical trials, will introduce Trialbee Honey™ Omnichannel, a powerful multichannel approach to global patient recruitment, at CNS Summit on Nov. 17-20 in Boca Raton, Florida.

Aerin Medical Inc. announced today that the Centers for Medicare and Medicaid Services (CMS) assigned physician and facility payment for a new Category I Current Procedural Terminology (CPT®) code that includes the use of VivAer® to repair nasal valve collapse (NVC) when performed in the office and outpatient surgical settings.

Genome Insight and Kun-hee Lee Child Cancer & Rare Disease Project Team of SNUH (Seoul National University Hospital), funded by the family of ex-Samsung Group Chairman Kun-hee Lee, announces today a collaborative study for a whole genome sequencing (WGS)-based approach to pediatric solid cancer diagnosis in the clinical setting.

Rockley Photonics Holdings Limited (NYSE: RKLY) (“Rockley”) today announced a groundbreaking 4-Kelvin performance demonstration with its monolithic silicon photonics electro-absorption modulator technology that is key to the development of next-generation cryogenic interconnect technology.

DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology based upon targeting the protein tyrosine phosphatase (PTP) family of enzymes.

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced it has received approval from the Italian Medicines Agency (AIFA) to commence patient enrollment in Italy for PARADIGM, the Company’s Phase 2b clinical trial of its lead drug candidate PrimeC in the treatment of amyotrophic lateral sclerosis (ALS).

Eli Lilly and Company will attend the fifth annual Evercore ISI HealthCONx Conference on Wednesday, Nov. 30, 2022.